Tuesday 10th August 2021
ALS Life Sciences are pleased to announce the acquisition of a 49% stake in NUVISAN, a pharmaceutical testing business with operations in Germany and France. Founded in 1979, NUVISAN operates in contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) markets providing drug testing services throughout the pharmaceutical development cycle in the fast-growing outsourced market.
The acquisition represents an expansion of ALS’ pharmaceutical offering into the drug development part of the supply chain which has a global market size of €154bn euros. The acquisition provides the platform for ALS to expand its offering from quality control testing into ‘upstream’ services in research and development which constitutes the majority of client spend. Growth of this area of the market is driven by major pharmaceutical companies outsourcing drug development research and CRO / CDMO testing due to increasing in demand for these services.
Managing Director and CEO of ALS, Raj Naran commented “This is an important and highly strategic acquisition for us. We have demonstrated our capacity of acquiring new businesses into our existing Life Sciences network and NUVISAN will take our presence in the attractive Life Sciences market to the next level. NUVISAN will become the ‘Centre of Excellence’ for innovation and technology research and development for the entire ALS Pharmaceutical network and here in the UK we look forward to welcoming this new business stream into the ALS Life Sciences group and all the great opportunities that it will bring.”
If you would like any information about the range of Pharmaceutical testing that we offer, please do not hesitate to contact our Team at Ely on 01353 660040 or visit our website, www.als-testing.co.uk/services/pharmaceuticaltesting.